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Background: Local and systemic inflammation is implicated in the pathophysiology of Obstruc-
tive Sleep Apnea (OSA). Exhaled breath condensate (EBC) is a non-invasive sampling method
for the lower airways. However, it is important to consider the potential effect of the systemic
origin whereas systemic inflammation is significantly elevated. This prospective study was de-
signed to investigate whether airway inflammation is significantly related to plasma leptin
levels in OSA patients. Simultaneously, it was designed to investigate whether inflammatory
variables predict parameters expressing disease severity and finally whether smoking habit
affect the above measurements.
Patients & Methods: About 45 OSA patients (mean AHI 40 25, 28 smokers) and 25 healthy
controls (AHI< 5, 15 smokers) were studied and underwent overnight diagnostic polysomno-
graphy. We measured pH, 8-isoprostane, TNF-a and IL-6 in EBC and leptin in plasma. Plausible
associations between leptin and inflammatory parameters were analyzed after adjustment for
proper variables. Similar associations between inflammatory variables and parameters of dis-
ease severity were also performed.
Results: An increased level of leptin and respective increase of inflammatory variables was
found. No significant association was observed between parameters of EBC and plasma leptin
levels. A part of the parameters of disease severity is significantly associated with pH and 8-
isoprostane. Smoking did not seem to be a critical confounding factor for evaluation of the
above measurements.
Conclusions: Increased levels of leptin were not associated with the observed airway inflam-
mation in OSA. The observed airway inflammation seemed to be independent of smoking habit
with limited association with disease severity.
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1400 S. Antonopoulou et al.Introduction cardiovascular disease, non well-controlled hypertension,Obstructive sleep apnea (OSA) is characterized by repeti-
tive episodes of upper airway closure during sleep associ-
ated with excessive daytime sleepiness and abnormalities
in cardiopulmonary and metabolic function. Several studies
have implicated airway1,2 and systemic3,4 inflammation in
the pathophysiology of this seemingly all-mechanical prob-
lem. These inflammatory changes are mainly attributed to
biomarkers expressing oxidative stress or cytokines related
to obesity.5,6
Leptin, a 16 kD adipokine, regulates weight centrally
and it is also a part of a cytokine network which governs
the inflammatory-immune response by releasing proinflam-
matory cytokines.7 The already reported association be-
tween OSA and hyperleptinemia may be explained by the
common link to obesity.8,9 However, several authors have
reported elevated leptin levels in patients with OSA even
after controlling for obesity measures, possibly through
mechanisms which involve the effects of hypoxemia, sleep
fragmentation or heightened sympathetic activity.10,11
Exhaled breath condensate (EBC) is a non-invasive
sampling method, easily repeatable, safe and useful for
sampling the airways and monitoring airway inflamma-
tion.12,13 Despite the traditional theory that most of the
mediators are coming from the lower airways (involving
bronchi and alveoli), it is important to consider the poten-
tial effect of the systemic origin where systemic inflamma-
tion is significantly elevated.12,14
Since leptin is associated with systemic inflammation,
we hypothesized that the possible increase of leptin levels
might also be related to a respective activity in airway
inflammation. We therefore assessed airway inflammation
by measuring the levels of 8-isoprostane, interleukin-6 (IL-
6), Tumor Necrosis Factor-alpha (TNF-a) and pH in EBC and
studied their plausible relation with plasma levels of leptin.
In order to eliminate confounding factors which affect the
above measurements, all associations were analyzed after
taking all the proper adjustments into consideration. As
a secondary outcome, we investigated whether values of
inflammatory variables and particularly EBC pH e a param-
eter measurable in the field e are affected by smoking
habit and predict the severity indexes of the disease.
Methods
Study subjects
We studied 112 consecutive patients referred to Sleep
Laboratory of the 1st Respiratory Department of Athens
University Medical School with symptoms suggestive of OSA,
for further diagnostic investigation. After a full night
diagnostic polysomnography, evaluation of inclusion and
exclusion criteria of the study, 45 OSA patients (37 males,
age 52 12 years, BMI 33.5 7, 28 smokers) finally formed
our patients group. Patients with Apnea/Hypopnea Index
(AHI) 10 were included in the study. Exclusion criteria
were respiratory infection in the last 4 weeks, history of
chronic liver and renal failure, metabolic syndrome, malig-
nancy, daily hypercapnia as assessed by arterial carbon
dioxide tension (PaCO2), diabetes, clinical apparentincreased lipid profile, atopy, self-reported asthma or re-
versibility >12% of airway obstruction after administration
of a b2-agonist and finally Chronic Obstructive Pulmonary
Disease (COPD) as assessed by the current guidelines.15
Twenty-five healthy subjects non-randomly selected,
matched for age, gender and BMI, (18 males, age 51 7
years, BMI 31 3, 15 smokers) were used as control group.
In all control subjects, OSA was excluded by using an over-
night diagnostic polysomnography. They were mainly re-
cruited from a population used as healthy subjects in
other studies of our group. Control subjects had AHI <5,
no significantly reported symptoms of daytime sleepiness
as assessed by Epworth Sleepiness Scale (ESS), no history
of medical diseases, were non-atopic, and were not receiv-
ing any daily medication. None of them had a history of re-
spiratory infection in the last 4 weeks before enrollment.
Written informed consent was obtained from all subjects,
and the study was approved by the institutional ethics
committee.
OSA variables
Polysomnography
ESS was used in all subjects for assessment of subjective
daytime sleepiness.16 Simultaneously, body weight and
height were evaluated in order to calculate the BMI
(weight/height2 in Kg/m2). Neck circumference and hip to
waist ratio were also measured.
Overnight polysomnography (Alice 4, Respironics, Inc,
Murryville, PA, USA) was performed between 11 pm to 6 am
according to standard procedure.17 Definitions for respira-
tory events were the following: (1) Obstructive apnea:
complete cessation of airflow with continued paradoxical
chest and abdominal movement for >10 s, (2) Hypopnea:
reduction of airflow of >50% from baseline for >10 s in as-
sociation with a 4% desaturation or EEG arousal. The num-
ber of events per hour of sleep was obtained by dividing the
total number of events by the total sleep time (TST) and
was defined as the AHI. OSA severity was assessed by num-
ber of AHI, mean duration of AH in seconds, lowest and
mean oxygen saturation (SaO2) %, total time in minutes
with saturation <90%, and the number of 4% drops in oxy-
gen saturation during TST defined as ‘‘Oxygen Desaturation
Index’’ (ODI).
Lung function
Pulmonary function tests were measured by a dry spirom-
eter (Vica-test, Model VEP2; Mijnhardt; Rotterdam, Hol-
land). Forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC) were measured according to
the American Thoracic Society guidelines.18 Reversibility
test was performed according to the GOLD guidelines.15
Exhaled breath condensate
EBC was collected and processed according to recently
published recommendations12 by using a condenser
(EcoScreen; Jaeger, Wurzburg, Germany). The condensate
(at least 1 ml) was collected and immediately transferred
to Eppendorf tubes and was stored at 70 C. All variables
with exception of pH were measured within 3 months from
the initial storage.
Leptin and airway inflammation in OSA 1401Measurement of inflammatory mediators
Leptin was assayed using an enzyme immunoassay (ELISA)
(Biosource Europe, Nivelles, Belgium). The detection limit
of the assay was 3.5 ng/ml. 8-Isoprostane concentration
was determined by a specific enzyme immunoassay kit
(Cayman Chemicals, Ann Arbor, MI, USA), as previously
described.19 The detection limit of the assay was 5 pg/ml.
TNF-a was measured by ELISA using an equivalent kit with
detection limit of the assay 0.09 pg/ml (Biosource Europe,
Nivelles, Belgium). IL-6 was measured by ELISA using a rele-
vant kit with detection limit of the assay 0.1 pg/ml (Ultra
sensitive Biocource, Europe, Nivelles, Belgium). pH was
measured, as previously described, using a pHmeter (Con-
sort P-903).20
Study protocol
On day 1, all subjects underwent a medical history and
medical examination by an experienced pneumonologist,
spirometry for measuring FEV1, FEV1/FVC before and after
bronchodilation, biochemical blood tests for electrolytes,
lipid profile, renal and liver function and blood gases for
PaCO2 assessment. Patients eligible for the study under-
went one night diagnostic polysomnography. In eligible sub-
jects, BMI, neck circumference, hip to waist ratio and
Epworth Sleepiness Scale were also assessed. EBC collec-
tion and venous blood samples for leptin measurement
were obtained at 6 am immediately after the end of the
overnight diagnostic polysomnography procedure. Smoking
was not permitted for the whole night until time of samples
drawing.
Statistical analysis
Data is presented as mean SD. Statistical comparisons
between two groups were estimated with unpaired t-test
except from non-normally distributed values (mean SaO2
%, TSaO2< 90 % [min]), where Mann-Whitney test was
used. To assess the independent association between leptin
and inflammatory mediators, a linear regression model was
used. Leptin was considered to be the dependent variableFigure 1 Flow chart forafter adjusting for BMI, age, neck circumference, hip to
waist ratio and smoking habit and inflammatory variables
were the independent ones. To further explore the
relationship between leptin, inflammatory mediators and
parameters of disease severity, a multivariate linear regres-
sion model was used with similar adjustments for leptin and
additional adjustments for inflammatory variables for
smoking, age and BMI. In this model, dependent variables
were leptin and inflammatory variables and independent
parameters of disease severity. Data for regression analysis
is presented with R2 for the whole model and standardized
b coefficient. p< 0.05 was considered significant. SPSS 12.0
(Chicago IL, USA) was used for analysis.
Results
Flow chart for subjects’ recruitment is presented in Fig. 1.
Subjects’ characteristics are summarized in Tables 1 (all)
and 2 (smokers and non-smokers).
Variables of interest
Leptin
Leptin values are presented in Fig. 2. Leptin levels were sig-
nificantly higher in OSA patients compared to normal sub-
jects (24 16 ng/ml vs. 8 3 ng/ml, p< 0.0001). Smoking
OSA patients did not significantly differ from non-smoking
ones (25 15 ng/ml vs. 23 17 ng/ml, pZ 0.8). Both smok-
ing and non-smoking OSA patients had significantly higher
levels compared to groups of normal subjects.
EBC variables
8-Isoprostane, TNF-a, IL-6 and pH values are presented in
Fig. 3A, B, C, and D, respectively. 8-Isoprostane levels in
EBC were significantly higher in OSA patients compared
to normal subjects (30.5 19 pg/ml vs. 12 3 pg/ml,
p< 0.0001). Smoking OSA patients did not significantly differ
from non-smoking ones (30 19 pg/ml vs. 31 19 pg/ml,
pZ 0.7). TNF-a levels in EBC were significantly higher in
OSA patients compared to normal subjects (1.4 0.9 pg/
ml vs. 0.64 0.3 pg/ml, pZ 0.0002). Smoking OSA patients
did not significantly differ from non-smoking onessubjects’ recruitment.
Table 1 Subjects’ characteristics
Variables Normals
nZ 25
OSA patients
nZ 45
p Value
Age, yr 51 7 52 12 0.67
Smoking (pack-years) 44 21 47 34 0.82
BMI (kg/m2) 31 3 33.5 7 0.06
ESS 0.6 0.9
(0e3)
8 4
(2e19)
NA
TST (min) 272 39 282 53 0.9
AHI <5 39 25 <0.0001
Mean duration of
AH in sec min sec
NA 40 7 NA
Minimum SaO2% 91 3 78 12 <0.0001
Mean SaO2% 95 3 88 7 <0.0001
ODI 1.4 0.8 41 28 <0.0001
TSaO2 <90 %(min) 1.7 0.6 48 67 <0.0001
FEV1% pred 99 10 107 25 0.12
Data is presented as mean SD except that of ESS where ranges
are also provided.
Abbreviations: OSA: Obstructive Sleep Apnoea; BMI: Body Mass
Index; ESS: Epworth Sleepiness Scale; AHI: Apnea/Hypopnea in-
dex; SaO2: Oxygen saturation; ODI: Oxygen Desaturation Index;
TSaO2 <90 (min): Total time in minutes during which SaO2 was
lower than 90%; TST: Total Sleep Time in minutes; FEV1: Forced
Expiratory Volume in 1 s; NA: Not Applicable.
Figure 2 Plasma leptin concentration in control subjects
[nZ 25,, smokers nZ 156, non-smokers nZ 107] and pa-
tients with Obstructive Sleep Apnoea (OSA) [nZ 57-, smokers
nZ 28:, non-smokers nZ 17;]. Each symbol represents one
individual. Horizontal bars represent mean values. See text for
details.
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EBC were significantly higher in OSA patients compared to
normal subjects (0.53 0.3 pg/ml vs. 0.21 0.2 pg/ml,
pZ 0.03). Smoking OSA patients did not significantly differ
from non-smoking ones (0.54 0.3 pg/ml vs. 0.48 0.3 pg/
ml, pZ 0.4). pH levels in EBC were significantly lower in
OSA patients compared to normal subjects (7.44 0.2 vs.
7.64 0.1, pZ 0.0009). pH levels in EBC did not significantlyTable 2 Subjects’ characteristics after subdivided according to
Variables OSA Normal
Smokers
nZ 28 5Fe23M
Non-smokers
nZ 17 3Fe14M
Smoker
nZ 15
Age, yr 51 10 54 14 52 7
Smoking (pack-years) 47 34 0 44 2
BMI (kg/m2) 35 7 32 6 32 3
ESS 8 5
(2e19)
8 4
(3e16)
0.7 0
(0e3)
TST (min) 290 46 271 62 289 8
AHI 44 28 31 19 <5
Mean duration of
AH in seconds
37 6 38 7 NA
Minimum SaO2% 77 14 80 8 92 2
Mean SaO2% 87 8 90 5 95 3
ODI 44 30 35 24 1.4 0
TSaO2 <90% (min) 58 77 33 44 1.8 0
FEV1% pred 104 26 112 21 97 8
Data is presented as mean SD except that of ESS where ranges are
Bold letters indicate statistical significant difference.
* within each group ** between OSA and normals [#smokers and ^non
Abbreviations: F: Female; M: Male; OSA: Obstructive Sleep Apnoea; B
Hypopnea Index; SaO2: Oxygen saturation; ODI: Oxygen Desaturation
was lower than 90%; TST: Total Sleep Time in minutes; FEV1: Forceddiffer between OSA smokers and non-smokers (7.43 0.2 vs.
7.45 0.2, pZ 0.7). Both smoking and non-smoking OSA pa-
tients had significantly lower levels compared to the related
groups of normal subjects.Linear regression data
Linear regression data between leptin (dependent variable)
after adjustment for age, BMI, neck circumference, hip tosmoking habit
s p Value* p Value**
s
4Fe11M
Non-smokers
nZ 10 3Fe7M
# ^
50 7 0.5 0.5 0.8 0.43
1 0 NA NA 0.7 NA
29 3 0.13 0.07 0.1 0.3
.9 0.5 0.8
(0e3)
0.9 0.9 NA NA
6 271 62 0.3 0.6 0.8
<5 0.09 NA <0.0001 <0.0001
NA 0.28 NA NA NA
91 3 0.4 0.7 <0.0001 <0.0001
96 4 0.2 0.8 <0.0001 <0.0001
.7 1.3 0.8 0.4 0.7 <0.0001 <0.0001
.7 1.7 0.6 0.2 0.7 <0.0001 <0.0001
101 13 0.3 0.38 0.3 0.2
also provided.
-smokers, respectively].
MI: Body Mass Index; ESS: Epworth Sleepiness Scale; AHI: Apnea/
Index; TSaO2 <90 (min): Total time in minutes during which SaO2
Expiratory Volume in 1 s; NA: Not Applicable.
Figure 3 A, B, C, D: 8-Isoprostane, TNF-a, IL-6 and pH values, respectively in Exhaled Breath Condensate (EBC) in control sub-
jects [nZ 25,, smokers nZ 156, non-smokers nZ 107] and patients with Obstructive Sleep Apnoea (OSA) [nZ 57-, smokers
nZ 28:, non-smokers nZ 17;]. Each symbol represents one individual. Horizontal bars represent mean values. See text for de-
tails. Detection limits for 8-isoprostane, TNF-a and IL-6 are 5 pg/ml, 0.09 pg/ml and 0.1 pg/ml, respectively.
Leptin and airway inflammation in OSA 1403waist ratio, smoking (pack-years) and parameters of in-
flammation in EBC (independent variables) did not show
any significant association (standardized coefficient were
0.2, 0.08, 0.15, 0.24 with p value 0.14, 0.6, 0.3, 0.1 for
IL-6, pH, 8-isoprostane and TNF-a, respectively). Adjusted
R2 for the whole model was 0.06. Similar results were also
observed for normal subjects (data for normals is not
shown).
Linear regression data between leptin (dependent vari-
able) after adjustment for age, BMI, neck circumference,
hip to waist ratio and smoking (pack-years), inflammatory
parameters of EBC (dependent variables) adjusted for age,
smoking habit and BMI and variables expressing disease
severity (independent variables) revealed the following
significant findings: pH was significantly associated with
mean AH duration in seconds and ODI (adjusted R2 0.2 for
the whole model, b coefficient 0.17, pZ 0.02 and b coeffi-
cient 0.22, pZ 0.03, respectively). 8-Isoprostane was sig-
nificantly associated with AH duration (adjusted R2 0.25
for the whole model, b coefficient 0.3, pZ 0.03). For therest non-mentioned data, all plausible associations either
in OSA patients or normal subjects revealed no significance.Discussion
The important and novel finding of this study is the
absence of significant relationship between the increased
levels of leptin and increased airway inflammation in
OSA. Moreover, a parameter measurable in the field, pH,
seems to predict limited but interesting part of disease
severity.
Our study confirms previous ones regarding the presence
of hyperleptinemia and local airway inflammation in
OSA.2,8,10 The different values for EBC mediators compared
to previous studies might be attributed to the larger num-
bers of patients selected in our study compared to previous
ones, as well as to different standardization procedures and
assays which mainly affect measurements in different
laboratories.
1404 S. Antonopoulou et al.The critical step of studies involving OSA patients and
investigating the role of hormones of adipose tissue and the
underlying systemic and airway inflammation, is to select
a homogenous study population without significant co-
morbidities in order to eliminate any plausible bias on the
evaluation process. Another critical issue for leptin evalu-
ation is the proper adjustments for variables which might
affect its values.8,9,21,22,23,24
In our study, we tried to eliminate all the above
dependent variables by excluding patients with hypercap-
nia, draw blood samples in a specific time and adjust leptin
in regression analysis for all the remaining confounding
factors. After this detailed protocol and the proper adjust-
ments, we did not find any association between leptin and
airway variables in EBC. The recently published recommen-
dations of EBC consider a potential effect of systemic
inflammation on EBC mediators as important, but with no
study to be existed in order to confirm the above theory.12
Previous data showed that leptin stimulates airway inflam-
matory cells’ chemotaxis and enhances their functional
capacity by leading to oxidative burst and cytokine
secretion.25,26 Based on this data, we expected to find
a good association between hyperleptinemia and airway in-
flammatory process either in the direction of oxidative
stress (8-isoprostane) or cytokine secretion (TNF-a). How-
ever, our study failed to show a close relation between sys-
temically evaluated leptin and airway inflammation. This
observation might mean that EBC is not influenced by the
leptin induced systemic inflammation but simultaneously
might represent some study limitations mainly attributing
to the mediators studied and the absence of any data relat-
ing to leptin airway expression. Regarding the first limita-
tion, we strongly believe that airway inflammation was
evaluated by three important components which include
both oxidative stress and cytokine secretion. As for the
second one, this interesting theory needs further studies
in order to be supported, as no relevant data exists so far.
By subdividing patients according to smoking habits, we
present some new data in this direction since all studies
dealing with EBC and OSA did not take smoking into
account.2,27,28 Smoking is considered as one of the risk fac-
tors for OSA with recent data to support a synergistic effect
between cigarette smoking and OSA on some of the bio-
chemical cardiovascular risk markers.29,30 The adjustment
of the EBC variables in relation to smoking eliminates any
plausible bias in the statistical procedure in this direction.
Surprisingly, and in contrast to already known data,12 smok-
ing seems not to influence any of the airway parameters
studied. This might be attributed to the time of EBC
collection [at 6 am immediately after an overnight poly-
somnography] in combination with the fact that all smoking
subjects were free from smoking at least 8e10 h before the
time that samples were drawn. Alternatively by the fact
that EBC collection technique (nasal clip) might eliminate
the consequence of smoking related nasal mucosal inflam-
mation12 and the plausible explanation that the overnight
mechanical model of ‘‘resistive breathing’’31 which leads
to generation of oxidative stress products as well as in local
induction of cytokines, overcomes any effect of smoking in
this process.
Another interesting finding of this study is the introduc-
tion of a new parameter in disease assessment, the pH. EBCpH is easy to be performed, measurable in the field,
reproducible, it has established normal values and may be
measured with portable equipment.12,32 The associations of
pH e after taking proper adjustments into consideration e
with mean duration of AH and ODI might be a coincidence.
Alternatively, if pH is considered, as a plausible parameter
of oxidative stress, it might be related either with the
model of resistive breathing or with that of hypoxia in-
duced-inflammation. The absence of any other significant
associations is not surprising, since in such a detailed me-
chanical model it is not easy for a parameter to express
the whole underlying severity variables. The significant as-
sociation between 8-isoprostane and AH duration partially
confirms previous findings and the already reported associ-
ation between oxidative stress and resistive breathing.31
Finally, we do not believe that the absence of significantly
daytime sleepiness as assessed by ESS might influence the
above results since its not always related with the underly-
ing severity of the disease.17
In conclusion, our study confirms previous ones regarding
the presence of hyperleptinemia and local airway inflam-
mation in OSA. The new findings of the study are the
absence of any relationship between the above, the
absence of any influence of smoking habit and the in-
troduction of a new variable, pH, which might express the
mechanical model of hypoxia and resistive breathing.
Conflict of interest statement
None of the authors have any conflicts to disclose.
References
1. Hatipog˘lu U, Rubinstein I. Inflammation and obstructive sleep
apnea syndrome. How many ways do I look at thee? Chest
2004;126:1e2.
2. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP,
Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative
stress, is increased in exhaled breath condensate of patients
with obstructive sleep apnea after night and is reduced by con-
tinuous positive airway pressure therapy. Chest 2003;124:
1386e92.
3. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated
C-reactive protein in patients with obstructive sleep apnea.
Circulation 2002;105:2462e4.
4. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-
media thickness and serum inflammatorymarkers in obstructive
sleep apnea. Am J Respir Crit Care Med 2005;172:625e30.
5. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of su-
peroxide from polymorphonuclear neutrophils in obstructive
sleep apnea. Impact of continuous positive airway pressure
therapy. Am J Respir Crit Care Med 2000;162:566e70.
6. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K,
Chrousos GP. Elevation of plasma cytokines in disorders of ex-
cessive daytime sleepiness: role of sleep disturbance and obe-
sity. J Clin Endocrinol Metab 1997;82:1313e6.
7. Otero M, Lago R, Gomez R, et al. Towards a proinflammatory
and immunomodulatory emerging role of leptin. Rheumatology
(Oxford) 2006;45(8):944e50.
8. Marik P. Leptin, obesity and obstructive sleep apnea. Chest
2000;118:569e71.
9. Barcelo A, Barbe F, Liompart E, et al. Neuropeptide Y and Lep-
tin in patients with obstructive sleep apnoea syndrome: role of
obesity. Am J Respir Crit Care Med 2005;171:183e7.
Leptin and airway inflammation in OSA 140510. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in
leptin levels, sympathetic drive and weight gain in obstructive
sleep apnea. Am J Physiol Heart Circ Physiol 2000;279:H234e7.
11. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y,
Kuriyama T. Sleep oxygen desaturation and circulating leptin
in obstructive sleep apnea-hypopnea syndrome. Chest 2005;
127:716e21.
12. Horva´th I, Hunt J, Barnes PJ. Exhaled breath condensate:
methodological recommendations and unresolved questions.
Eur Respir J 2005;26:523e48.
13. Kharitonov SA. Exhaled markers of inflammatory lung diseases:
ready for routine monitoring? Swiss Med Wkly 2004;134:175e92.
14. Rysz J, Kasielski M, Apanasiewicz J, et al. Increased hydrogen
peroxide in the exhaled breath of uraemic patients unaffected
by haemodialysis. Nephrol Dial Transplant 2004;19:158e63.
15. Global Initiative for Chronic Obstructive Lung Disease. Global
Strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO workshop
report. Bethesda, National Heart, Lung and Blood Institute,
April 2001; update of the Management Sections, GOLD website
(www.goldcopd.com). Date updated: July 2006.
16. Johns MW. A new method for measuring daytime sleepiness:
the Epworth sleepiness scale. Sleep 1991;14:540e5.
17. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002;
360:237e45.
18. Standardization of Spirometry, 1994 Update. American Tho-
racic Society. Am J Respir Crit Care Med 1995;152:1107e36.
19. Psathakis K, Papatheodorou G, Plataki M, et al. 8-Isoprostane,
a marker of oxidative stress, is increased in the expired breath
condensate of patients with pulmonary sarcoidosis. Chest
2004;125:1005e11.
20. Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P,
Loukides S. pH in expired breath condensate of patients with
inflammatory airway diseases. Am J Respir Crit Care Med
2002;165:1364e70.21. Reseland JE, Mundal HH, Hollung K, et al. Cigarette smoking
may reduce plasma leptin concentration via catecholamines.
Prostaglandins Leukot Essent Fatty Acids 2005;73(1):43e9.
22. Nicklas BJ, Tomoyasu N, Muir J, Goldberg AP. Effects of ciga-
rette smoking and its cessation on body weight and plasma lep-
tin levels. Metabolism 1999;48:804e8.
23. Shimura R, Tatsumi K, Nakamura A, et al. Fat accumulation,
leptin, and hypercapnia in obstructive sleep apnea-hypopnea
syndrome. Chest 2005;127:543e9.
24. Patel SR, Palmer LJ, Larkin EK, Jenny NS, White DP, Redline S.
Relationship between obstructive sleep apnea and diurnal lep-
tin rhythms. Sleep 2004;27:235e9.
25. Galdefie-Chezet F, Poulin A, Vasson MP. Leptin regulates func-
tional capacities of polymorphonuclear neutrophils. Free Radic
Res 2003;37:809e14.
26. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regula-
tor of inflammation. Best Pract Res Clin Endocrinol Metab
2005;19:547e66.
27. Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D. Inflamma-
tory mediators in exhaled breath condensate of children with
obstructive sleep apnoea syndrome. Chest 2006;130:143e8.
28. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP,
Gramiccioni E, Barnes PJ. Increased 8-isoprostane and inter-
leukin-6 in breath condensate of obstructive sleep apnea pa-
tients. Chest 2002;122:1162e7.
29. Wetter DW, Young TB, Bidwell TR, Badr MS, Palta M. Smoking as
a risk factor for sleep disordered breathing. Arch Intern Med
1994;154:2219e24.
30. Lavie L, Lavie P. Smoking interacts with sleep apnea to in-
crease cardiovascular risk. Sleep Med 2008;9:247e53.
31. Vassilakopoulos T, Roussos C, Zakynthinos S. The immune re-
sponse to resistive breathing. Eur Respir J 2004;24:1033e43.
32. Paget-Brown AO, Ngamtrakulpanit L, Smith A, et al. Normative
data for pH of exhaled breath condensate. Chest 2006;129:
426e30.
